Preclinical inflammatory rheumatic diseases: An overview and relevant nomenclature

Rheumatic Disease Clinics of North America

Volumn 40, Issue 4, 2014, Pages 569-580

  Raza, Karim ^a,b   Gerlag, Danielle M ^c,d  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b SANDWELL AND WEST BIRMINGHAM HOSPITALS NHS TRUST   (United Kingdom)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Early; Preclinical; Prediction; Prevention; Rheumatoid arthritis; Risk

Indexed keywords

OMEGA 3 FATTY ACID; RITUXIMAB; VITAMIN D;

AUTOIMMUNE DISEASE; DISEASE DURATION; ENVIRONMENTAL FACTOR; GENETIC RISK; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOLOGY; INSULIN DEPENDENT DIABETES MELLITUS; LIFESTYLE MODIFICATION; NOMENCLATURE; PATHOGENESIS; PREDICTION; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SYMPTOM; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; ARTHRITIS, RHEUMATOID; ASYMPTOMATIC DISEASE; DISEASE COURSE; EARLY DIAGNOSIS; GENETICS; PATHOPHYSIOLOGY; RHEUMATIC DISEASES;

ARTHRITIS, RHEUMATOID; ASYMPTOMATIC DISEASES; DISEASE PROGRESSION; EARLY DIAGNOSIS; GENE-ENVIRONMENT INTERACTION; HUMANS; RHEUMATIC DISEASES; TERMINOLOGY AS TOPIC;

EID: 84908070390     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2014.07.001     Document Type: Review

References (58)

1. van der Linden M.P., le Cessie S., Raza K., et al. Long-term impact of delay in assessment of patients with early arthritis. Arthritis Rheum 2010, 62(12):3537-3546.
2. Finckh A., Liang M.H., van Herckenrode C.M., et al. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis. Arthritis Rheum 2006, 55(6):864-872.
3. Tillett W., Jadon D., Shaddick G., et al. Smoking and delay to diagnosis are associated with poorer functional outcome in psoriatic arthritis. Ann Rheum Dis 2013, 72(8):1358-1361.
4. Aho K., Palosuo T., Raunio V., et al. When does rheumatoid disease start?. Arthritis Rheum 1985, 28(5):485-489.
5. Kurki P., Aho K., Palosuo T., et al. Immunopathology of rheumatoid arthritis. Antikeratin antibodies precede the clinical disease. Arthritis Rheum 1992, 35(8):914-917.
6. Aho K., von Essen R., Kurki P., et al. Antikeratin antibody and antiperinuclear factor as markers for subclinical rheumatoid disease process. JRheumatol 1993, 20(8):1278-1281.
7. van Steenbergen H.W., Huizinga T.W., van der Helm-van Mil A.H. The preclinical phase of rheumatoid arthritis: what is acknowledged and what needs to be assessed?. Arthritis Rheum 2013, 65(9):2219-2232.
8. Gerlag D.M., Raza K., van Baarsen L.G., et al. EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. Ann Rheum Dis 2012, 71(5):638-641.
9. Rakieh C., Nam J.L., Hunt L., et al. Predicting the development of clinical arthritis in anti-CCP positive individuals with non-specific musculoskeletal symptoms: a prospective observational cohort study. Ann Rheum Dis 2014, [Epub ahead of print].
10. Buckley C.D., Gilroy D.W., Serhan C.N., et al. The resolution of inflammation. Nat Rev Immunol 2013, 13(1):59-66.
11. Raza K., Saber T.P., Kvien T.K., et al. Timing the therapeutic window of opportunity in early rheumatoid arthritis: proposal for definitions of disease duration in clinical trials. Ann Rheum Dis 2012, 71(12):1921-1923.
12. Arnett F.C., Edworthy S.M., Bloch D.A., et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31(3):315-324.
13. Aletaha D., Neogi T., Silman A.J., et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010, 69(9):1580-1588.
14. Stack R.J., Sahni M., Mallen C.D., et al. Symptom complexes at the earliest phases of rheumatoid arthritis: a synthesis of the qualitative literature. Arthritis Care Res (Hoboken) 2013, 65(12):1916-1926.
15. Stack R.J., van Tuyl L.H., Sloots M., et al. Symptom complexes in patients with seropositive arthralgia and in patients newly diagnosed with rheumatoid arthritis: a qualitative exploration of symptom development. Rheumatology (Oxford) 2014, 53(9):1646-1653.
16. Gregersen P.K., Silver J., Winchester R.J. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987, 30(11):1205-1213.
17. Begovich A.B., Carlton V.E., Honigberg L.A., et al. Amissense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet 2004, 75(2):330-337.
18. Padyukov L., Silva C., Stolt P., et al. Agene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis. Arthritis Rheum 2004, 50(10):3085-3092.
19. Klareskog L., Stolt P., Lundberg K., et al. Anew model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum 2006, 54(1):38-46.
20. Kallberg H., Padyukov L., Plenge R.M., et al. Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. Am J Hum Genet 2007, 80(5):867-875.
21. Bos W.H., Ursum J., de Vries N., et al. The role of the shared epitope in arthralgia with anti-cyclic citrullinated peptide antibodies (anti-CCP), and its effect on anti-CCP levels. Ann Rheum Dis 2008, 67(9):1347-1350.
22. Haj Hensvold A., Magnusson P.K., Joshua V., et al. Environmental and genetic factors in the development of anticitrullinated protein antibodies (ACPAs) and ACPA-positive rheumatoid arthritis: an epidemiological investigation in twins. Ann Rheum Dis 2013, [Epub ahead of print].
23. van der Woude D., Lie B.A., Lundstrom E., et al. Protection against anti-citrullinated protein antibody-positive rheumatoid arthritis is predominantly associated with HLA-DRB1*1301: a meta-analysis of HLA-DRB1 associations with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis in four European populations. Arthritis Rheum 2010, 62(5):1236-1245.
24. van de Sande M.G., de Hair M.J., van der Leij C., et al. Different stages of rheumatoid arthritis: features of the synovium in the preclinical phase. Ann Rheum Dis 2011, 70(5):772-777.
25. de Pablo P., Chapple I.L., Buckley C.D., et al. Periodontitis in systemic rheumatic diseases. Nat Rev Rheum 2009, 5(4):218-224.
26. Scher J.U., Bretz W.A., Abramson S.B. Periodontal disease and subgingival microbiota as contributors for rheumatoid arthritis pathogenesis: modifiable risk factors?. Curr Opin Rheum 2014, 26(4):424-429.
27. Mikuls T.R., Thiele G.M., Deane K.D., et al. Porphyromonas gingivalis and disease-related autoantibodies in individuals at increased risk of rheumatoid arthritis. Arthritis Rheum 2012, 64(11):3522-3530.
28. Willis V.C., Demoruelle M.K., Derber L.A., et al. Sputum autoantibodies in patients with established rheumatoid arthritis and subjects at risk of future clinically apparent disease. Arthritis Rheum 2013, 65(10):2545-2554.
29. Brusca S.B., Abramson S.B., Scher J.U. Microbiome and mucosal inflammation as extra-articular triggers for rheumatoid arthritis and autoimmunity. Curr Opin Rheum 2014, 26(1):101-107.
30. Shi J., Knevel R., Suwannalai P., et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc Natl Acad Sci USA 2011, 108(42):17372-17377.
31. McInnes I.B., Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007, 7(6):429-442.
32. Yarwood A., Han B., Raychaudhuri S., et al. Aweighted genetic risk score using all known susceptibility variants to estimate rheumatoid arthritis risk. Ann Rheum Dis 2013, [Epub ahead of print].
33. Sparks J.A., Chen C.Y., Jiang X., et al. Improved performance of epidemiologic and genetic risk models for rheumatoid arthritis serologic phenotypes using family history. Ann Rheum Dis 2014, [Epub ahead of print].
34. van de Stadt L.A., Witte B.I., Bos W.H., et al. Aprediction rule for the development of arthritis in seropositive arthralgia patients. Ann Rheum Dis 2013, 72(12):1920-1926.
35. van der Helm-van Mil A.H., le Cessie S., van Dongen H., et al. Aprediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: how to guide individual treatment decisions. Arthritis Rheum 2007, 56(2):433-440.
36. van der Helm-van Mil A.H., Detert J., Cessie S., et al. Validation of a prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: moving toward individualized treatment decision-making. Arthritis Rheum 2008, 58(8):2241-2247.
37. Kelly S., Humby F., Filer A. Ultrasound-guided synovial biopsy: a safe, well-tolerated and reliable technique for obtaining high-quality synovial tissue from both large and small joints in early arthritis patients. Ann Rheum Dis 2013, [Epub ahead of print].
38. de Hair M.J., Zijlstra I.A., Boumans M.J., et al. Hunting for the pathogenesis of rheumatoid arthritis: core-needle biopsy of inguinal lymph nodes as a new research tool. Ann Rheum Dis 2012, 71(11):1911-1912.
39. Filer A., de Pablo P., Allen G., et al. Utility of ultrasound joint counts in the prediction of rheumatoid arthritis in patients with very early synovitis. Ann Rheum Dis 2011, 70(3):500-507.
40. van Steenbergen H.W., van Nies J.A., Huizinga T.W., et al. Characterising arthralgia in the preclinical phase of rheumatoid arthritis using MRI. Ann Rheum Dis 2014, [Epub ahead of print].
41. van Steenbergen H.W., van Nies J.A., Huizinga T.W., et al. Subclinical inflammation on MRI of hand and foot of anti-citrullinated peptide antibody-negative arthralgia patients at risk for rheumatoid arthritis. Arthritis Res Ther 2014, 16(2):R92.
42. van de Stadt L.A., Bos W.H., Meursinge Reynders M., et al. The value of ultrasonography in predicting arthritis in auto-antibody positive arthralgia patients: a prospective cohort study. Arthritis Res Ther 2010, 12(3):R98.
43. Kallberg H., Ding B., Padyukov L., et al. Smoking is a major preventable risk factor for rheumatoid arthritis: estimations of risks after various exposures to cigarette smoke. Ann Rheum Dis 2011, 70(3):508-511.
44. de Hair M.J., Landewe R.B., van de Sande M.G., et al. Smoking and overweight determine the likelihood of developing rheumatoid arthritis. Ann Rheum Dis 2013, 72(10):1654-1658.
45. Manson J.E., Bassuk S.S., Lee I.M., et al. The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemp Clin Trials 2012, 33(1):159-171.
46. de Wit M., Abma T., Koelewijn-van Loon M., et al. Involving patient research partners has a significant impact on outcomes research: a responsive evaluation of the international OMERACT conferences. BMJ Open 2013, 3(5). pii:e002241.
47. Hewlett S., Wit M., Richards P., et al. Patients and professionals as research partners: challenges, practicalities, and benefits. Arthritis Rheum 2006, 55(4):676-680.
48. Combe B., Landewe R., Lukas C., et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007, 66(1):34-45.
49. Kumar K., Daley E., Carruthers D.M., et al. Delay in presentation to primary care physicians is the main reason why patients with rheumatoid arthritis are seen late by rheumatologists. Rheumatology (Oxford) 2007, 46(9):1438-1440.
50. Raza K., Stack R., Kumar K., et al. Delays in assessment of patients with rheumatoid arthritis: variations across Europe. Ann Rheum Dis 2011, 70(10):1822-1825.
51. Sheppard J., Kumar K., Buckley C.D., et al. 'I just thought it was normal aches and pains': a qualitative study of decision-making processes in patients with early rheumatoid arthritis. Rheumatology (Oxford) 2008, 47(10):1577-1582.
52. Kumar K., Daley E., Khattak F., et al. The influence of ethnicity on the extent of, and reasons underlying, delay in general practitioner consultation in patients with RA. Rheumatology (Oxford) 2010, 49(5):1005-1012.
53. Stack R.J., Shaw K., Mallen C., et al. Delays in help seeking at the onset of the symptoms of rheumatoid arthritis: a systematic synthesis of qualitative literature. Ann Rheum Dis 2012, 71(4):493-497.
54. Atkinson M.A., Eisenbarth G.S., Michels A.W. Type 1 diabetes. Lancet 2014, 383(9911):69-82.
55. Ziegler A.G., Rewers M., Simell O., et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 2013, 309(23):2473-2479.
56. Skyler J.S., Greenbaum C.J., Lachin J.M., et al. Type 1 Diabetes TrialNet-an international collaborative clinical trials network. Ann N Y Acad Sci 2008, 1150:14-24.
57. Matucci-Cerinic M., Allanore Y., Czirjak L., et al. The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategy. Ann Rheum Dis 2009, 68(9):1377-1380.
58. Minier T., Guiducci S., Bellando-Randone S., et al. Preliminary analysis of the Very Early Diagnosis of Systemic Sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for suspicion of systemic sclerosis. Ann Rheum Dis 2013, [Epub ahead of print].